SG11201606596PA - Multimeric fc proteins - Google Patents
Multimeric fc proteinsInfo
- Publication number
- SG11201606596PA SG11201606596PA SG11201606596PA SG11201606596PA SG11201606596PA SG 11201606596P A SG11201606596P A SG 11201606596PA SG 11201606596P A SG11201606596P A SG 11201606596PA SG 11201606596P A SG11201606596P A SG 11201606596PA SG 11201606596P A SG11201606596P A SG 11201606596PA
- Authority
- SG
- Singapore
- Prior art keywords
- multimeric
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403914A GB201403914D0 (en) | 2014-03-05 | 2014-03-05 | Proteins |
| GB201403915A GB201403915D0 (en) | 2014-03-05 | 2014-03-05 | Proteins |
| GBGB1405955.4A GB201405955D0 (en) | 2014-04-02 | 2014-04-02 | Proteins |
| GB201412648A GB201412648D0 (en) | 2014-07-16 | 2014-07-16 | Proteins |
| PCT/EP2015/054688 WO2015132365A1 (en) | 2014-03-05 | 2015-03-05 | Multimeric fc proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606596PA true SG11201606596PA (en) | 2016-09-29 |
Family
ID=52697365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606596PA SG11201606596PA (en) | 2014-03-05 | 2015-03-05 | Multimeric fc proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170081406A1 (en) |
| EP (1) | EP3114137A1 (en) |
| JP (1) | JP6851199B2 (en) |
| KR (1) | KR20160127821A (en) |
| CN (1) | CN106132994A (en) |
| AU (1) | AU2015226101B2 (en) |
| BR (1) | BR112016020377A2 (en) |
| CA (1) | CA2939201A1 (en) |
| IL (1) | IL247246A0 (en) |
| MX (1) | MX2016010953A (en) |
| RU (1) | RU2016139022A (en) |
| SG (1) | SG11201606596PA (en) |
| WO (1) | WO2015132365A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3114143B1 (en) | 2014-03-05 | 2020-07-08 | UCB Biopharma SRL | Multimeric fc proteins |
| WO2015168643A2 (en) | 2014-05-02 | 2015-11-05 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| GB201511787D0 (en) * | 2015-07-06 | 2015-08-19 | Ucb Biopharma Sprl | Proteins |
| GB201513033D0 (en) * | 2015-07-23 | 2015-09-09 | Ucb Biopharma Sprl | Proteins |
| BR112018014668A2 (en) * | 2016-01-27 | 2018-12-11 | Csl Behring Recombinant Facility Ag | recombinant igg fc multimers |
| CN109963869A (en) | 2016-05-23 | 2019-07-02 | 动量制药公司 | Composition relevant to modified Fc construct and method |
| US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
| EP3487534A4 (en) | 2016-07-22 | 2020-03-25 | Gliknik Inc. | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding |
| WO2018107082A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
| JP7146771B2 (en) | 2017-01-06 | 2022-10-04 | モメンタ ファーマシューティカルズ インコーポレイテッド | Compositions and methods for engineered Fc constructs |
| CN113201071A (en) * | 2017-03-28 | 2021-08-03 | 礼进生物医药科技（上海）有限公司 | Therapeutic agents and methods for enhancing immune response in tumor microenvironment |
| CN112004550A (en) * | 2017-12-14 | 2020-11-27 | 康诺贝林伦瑙有限公司 | Recombinant IgG Fc multimer for treating neuromyelitis optica |
| CN113271972A (en) * | 2018-11-14 | 2021-08-17 | Jn生物科学有限责任公司 | Multimeric hybrid Fc proteins for replacement of IVIG |
| BR112022003713A2 (en) | 2019-09-13 | 2022-08-09 | CSL Behring Lengnau AG | RECOMBINANT IGG FC MULTIMERS FOR THE TREATMENT OF IMMUNOCOMPLEX-MEDIATED KIDNEY DISEASES |
| WO2021111007A1 (en) * | 2019-12-06 | 2021-06-10 | CSL Behring Lengnau AG | Stable compositions of fc multimers |
| CN115724985A (en) * | 2021-08-27 | 2023-03-03 | 三生国健药业（上海）股份有限公司 | CDC platform antibody |
| CN117925664A (en) * | 2023-11-29 | 2024-04-26 | 上海科锐克医药科技有限公司 | Gene delivery vector for delivering human VEGF receptor fusion protein and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2713981C (en) * | 2008-02-08 | 2016-11-01 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| KR20100135808A (en) * | 2008-03-13 | 2010-12-27 | 바이오테스트 아게 | Agent for treating disease |
| JP2012515556A (en) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Stabilized Fc polypeptides with reduced effector function and methods of use |
| CA2849765C (en) * | 2011-09-26 | 2021-10-19 | Jn Biosciences Llc | Hybrid constant regions |
| JP2015524821A (en) * | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | Antibody or fusion protein multimerized via cysteine mutation and μ tail |
-
2015
- 2015-03-05 SG SG11201606596PA patent/SG11201606596PA/en unknown
- 2015-03-05 MX MX2016010953A patent/MX2016010953A/en unknown
- 2015-03-05 RU RU2016139022A patent/RU2016139022A/en not_active Application Discontinuation
- 2015-03-05 KR KR1020167027644A patent/KR20160127821A/en unknown
- 2015-03-05 EP EP15711066.9A patent/EP3114137A1/en not_active Withdrawn
- 2015-03-05 CN CN201580011852.3A patent/CN106132994A/en active Pending
- 2015-03-05 CA CA2939201A patent/CA2939201A1/en not_active Abandoned
- 2015-03-05 JP JP2016555472A patent/JP6851199B2/en active Active
- 2015-03-05 US US15/123,066 patent/US20170081406A1/en not_active Abandoned
- 2015-03-05 WO PCT/EP2015/054688 patent/WO2015132365A1/en active Application Filing
- 2015-03-05 BR BR112016020377A patent/BR112016020377A2/en not_active Application Discontinuation
- 2015-03-05 AU AU2015226101A patent/AU2015226101B2/en not_active Ceased
-
2016
- 2016-08-11 IL IL247246A patent/IL247246A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015226101A1 (en) | 2016-08-25 |
| IL247246A0 (en) | 2016-09-29 |
| EP3114137A1 (en) | 2017-01-11 |
| CA2939201A1 (en) | 2015-09-11 |
| JP6851199B2 (en) | 2021-03-31 |
| WO2015132365A1 (en) | 2015-09-11 |
| MX2016010953A (en) | 2016-11-29 |
| KR20160127821A (en) | 2016-11-04 |
| US20170081406A1 (en) | 2017-03-23 |
| BR112016020377A2 (en) | 2018-01-23 |
| AU2015226101B2 (en) | 2019-08-22 |
| JP2017509335A (en) | 2017-04-06 |
| RU2016139022A (en) | 2018-04-25 |
| CN106132994A (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247096A0 (en) | Multimeric fc proteins | |
| IL247246A0 (en) | Multimeric fc proteins | |
| HK1232136A1 (en) | P97-ids fusion proteins p97-ids | |
| PL3702450T3 (en) | Protein | |
| GB201418562D0 (en) | Peptides | |
| GB201415344D0 (en) | Protein | |
| HRP20182029T1 (en) | Uti fusion proteins | |
| HUE057808T2 (en) | Protein recovery | |
| IL248276A0 (en) | Carbohydrate-binding protein | |
| PL3099793T3 (en) | Protein | |
| GB201401877D0 (en) | Peptides | |
| EP3099320A4 (en) | Protein m related immunoglobulin-binding polypeptides | |
| EP3204427A4 (en) | Chimeric proteins | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| HK1253316A1 (en) | Peptides | |
| GB201517390D0 (en) | Protein variant analysis | |
| GB201412797D0 (en) | Proteins | |
| GB201412648D0 (en) | Proteins | |
| GB201412649D0 (en) | Proteins | |
| GB201412646D0 (en) | Proteins | |
| GB201406894D0 (en) | Proteins | |
| GB201414371D0 (en) | Protein modification | |
| GB201405955D0 (en) | Proteins | |
| GB201405952D0 (en) | Proteins | |
| GB201403912D0 (en) | Proteins |